MedTrace Logo

Human Epididymis Protein 4 in Endometrial Carcinoma

NCT03456791 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2018-08-14

No results posted yet for this study

Summary

Endometrial cancer represents the most common gynecologic cancer, and it is expected to become an even greater public health concern as the prevalence of obesity, one of the most common risk factors for endometrial cancer, increases worldwide.

Almost 20% of patients with endometrial cancer are in the premenopausal state and 10% are asymptomatic. In such a case, it is much harder to make an early diagnosis and usually they are probably diagnosed at advanced stages.

An earlier diagnosis represents an imperative goal to improve survival and prognosis of patients of endometrial cancer. Actually, there are no certified screening tools for endometrial cancer. Pelvic ultrasound as screening for endometrial cancer-reaches 80.5% of sensitivity, when endometrial echo is \> 5 mm, but it dramatically decreases to 20% in asymptomatic women; moreover, specificity is low (61%).

Conditions

Interventions

DIAGNOSTIC_TEST

Human epididymis protein 4

Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Hayam F Mohammad, MD · Ain Shams University

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2018-06-01
Completion
2018-07-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03456791 on ClinicalTrials.gov